Colorectal adenocarcinoma is the most common cancer in North America and the second
leading cause of cancer death in the USA (American Cancer Society, 1990). The expression …

Colorectal cancer is the third common cancer in this world, accounting for more than 1
million cases each year. However, detailed etiology and mechanism of colorectal cancer …

Increasing evidence indicates that Non-steroidal anti-inflammatory drugs (NSAIDs),
compounds that inhibit the enzymatic activity of cyclooxygenase (COX), can reduce the …

Cyclooxygenase (COX), the key regulatory enzyme for prostaglandin synthesis, is
transcribed from two distinct genes. COX-1 is expressed constitutively in most tissues …

Increasing epidemiological and experimental evidence implicates non-steroidal anti-
inflammatory drugs (NSAIDs) as anti-tumorigenic agents. The precise mechanisms whereby …

Epidemiologic studies have documented a 40–50% reduction in incidence of colorectal
cancer in individuals taking nonsteroidal antiinflammatory drugs (NSAIDs). Since NSAIDs …

Abstract Cyclooxygenase-2 (COX-2) is an inducible enzyme that regulates prostaglandin
synthesis and is overexpressed at sites of inflammation and in several epithelial cancers …

Genetic deletion or pharmacological inhibition of cyclooxygenase (COX)-2 abrogates
intestinal adenoma development at early stages of colorectal carcinogenesis. COX-2 is …

Colorectal cancer is the second leading cause of cancer deaths in the United States.
Despite proven screening strategies, less than 40% of eligible Americans undergo …

Adenomatous polyposis coli (APC) is inactivated in familial adenomatous polyposis and
sporadic colorectal cancer. Mice carrying defective APC (apcMin/+) spontaneously develop …